Anti-human DRD3 (Extracellular) Recombinant Monoclonal Antibody (HM0079)
Price range: $230.00 through $720.00
Anti-human DRD3 Recombinant Monoclonal Antibody (HM0079) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library, followed by structure-guided affinity optimization. The antibody recognizes an epitope (AA 2-19) located within the N-terminal extracellular flexible region of the D3 dopamine receptor (DRD3). It has been validated by ELISA using a recombinant epitope-Fc fusion antigen, by Western blot against a recombinant MBP-epitope fusion protein, and by Western blot detection of endogenous DRD3 protein in human cell lysates.
Also known as: hDRD3, DRD3, D3 dopamine receptor, and Dopamine receptor D3.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human DRD3 Recombinant Monoclonal Antibody |
| Antibody ID | HM0079 |
| Target Protein | D3 dopamine receptor |
| Target Protein Short Name | hDRD3 |
| UniProt Accession | P35462-1, P35462-3 |
| Molecular Weight | Human isoform 1: 44.2 kDa; Human isoform 3: 40.7 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | ASLSQLSGHLNYTCGAEN |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
D(3) dopamine receptor (DRD3) is a dopamine-responsive G protein-coupled receptor involved in neurotransmission, reward signaling, cognition, emotional regulation, and neuropsychiatric signaling pathways. DRD3 is predominantly expressed in limbic brain regions and has been associated with addiction biology, schizophrenia, Parkinson’s disease, mood disorders, and neuropharmacology research.
As a member of the dopamine receptor GPCR family, DRD3 is widely studied in neuroscience, receptor pharmacology, psychiatric disease research, and GPCR signaling biology.
Antibody Development
HM0079 was generated by phage-display selection using a mouse-derived antibody library. A recombinant epitope-Fc fusion protein containing the DRD3 epitope sequence was used as the selection antigen. After identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous human DRD3 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc-only control protein.
Validation conditions:
- Fc control protein
- Epitope-Fc fusion protein
- Detection substrate: TMB
Note: ELISA validation confirms binding to epitope-Fc fusion antigen. Full-length DRD3 protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis confirmed specific recognition of recombinant MBP-epitope fusion protein, with minimal signal against MBP control protein.
Validation conditions:
- MBP control protein
- MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous human DRD3 protein in human cell lysates under reducing conditions.
Validated samples:
- 293T cells
- HeLa cells
- HepG2 cells
Observed bands:
- Major immunoreactive bands were detected around 40–45 kDa, consistent with the expected molecular weight range of human DRD3 isoforms.
- Additional higher molecular weight bands may represent glycosylated receptor species, receptor-associated complexes, oligomeric forms, or modified GPCR-associated species.
| Size | 20 ul, 100 ul |
|---|
Related products
